Missed Nvidia at $4.50? This could be your second chance…

Analyst Targets

• Consensus rating: Strong Buy (18 of 26 analysts), average price target $478.50
• Q3 2026 consensus EPS: approximately $4.15, revenue estimate $111.49 billion
• Full-year 2026 EPS guidance (company): $19.50–$20.00; analyst consensus $19.85

What Just Happened

At least 11 health insurance companies that sold individual Medicare Advantage plans this year are abandoning the program for 2027, compared to seven carriers that quit for 2026. Eight of those are health system-affiliated insurers. Several others, including Molina Healthcare and Horizon BCBS New Jersey, will stay in Medicare Advantage only through special needs plans. Three Blue Cross Blue Shield plans, Wellmark, Mississippi, and North Dakota, will also discontinue coverage for 2027.

In early October, approximately 600,000 Humana Medicare Advantage members are expected to receive non-renewal notices informing them their plan will not exist in 2027. UnitedHealth confirmed approximately 390,000 of its own members will be affected by plan discontinuations. Taken together, at least 3.8 million enrollees will be forced to shop for new coverage for 2027. About 512,000 people in 14 states will need to find new carriers because their insurers are leaving their geographic areas. There will be no Medicare Advantage plans available in 181 counties, up from 67 this year.

The exits are not evenly distributed. Seven health system-owned insurers, including Christus Health Plan and Providence Health Plan, are among those departing. More than 64,000 Providence Medicare Advantage members are affected, most of them in Oregon. Christus Health Plan had nearly 9,000 Medicare Advantage members in New Mexico and Texas. These are not national carriers. Their departures signal that even organizations built around vertically integrated care delivery found the economics unworkable.

The Financial Context Heading into October 13

UNH’s Q2 2026 medical care ratio was 86.7%, down from 89.4% in Q2 2025, driven by benefit design and pricing discipline, member mix, and medical cost management. That improvement followed a brutal 2025, when the full-year adjusted medical care ratio reached 88.9%, with CMS Medicare funding reductions and accelerating cost trends cited as key drivers.

The Q3 read matters disproportionately. Seasonal utilization patterns typically push the third-quarter ratio higher than Q2, so the degree of sequential deterioration will tell investors whether the pricing actions taken for 2026 are actually holding. Humana’s exits target plans rated 3.5 stars or lower for the 2027 bonus year, and CEO Jim Rechtin has framed the strategy as returning the company to a sustainable pretax margin of at least 3% by 2028. UNH management faces the same fundamental question on October 13.

Why the Market Is Watching

CMS finalized an average payment increase of 2.48% for 2027 Medicare Advantage plans in April, valued at over $13 billion industry-wide. Analysts expect that adjustment to slow, rather than reverse, exit activity. That framing is critical: the rate increase was not enough to stop plans from folding. The question for UNH and Humana is whether their own 2027 bids, shaped around narrower geographies and lower-star exits, have finally matched pricing to cost reality.

Humana’s coverage will extend to just over 80% of U.S. counties in 2027, down from 85% currently. Humana expects to recapture roughly 40% of affected members into other plans it offers, leaving an estimated 360,000 members needing to find coverage elsewhere. That retention rate is the variable most likely to move Humana’s 2027 membership guidance when it reports.

Bull / Base / Bear for UNH on October 13

Bull: Q3 medical care ratio holds below 87%, management narrows the wide range on Q4 guidance, and the call confirms that 2027 plan exits position UNH for margin expansion rather than membership-driven revenue pressure. The stock re-rates toward the $478 average target.

Base: MCR comes in between 87% and 88.5%, consistent with seasonal norms. Management acknowledges uncertainty on 2027 member recapture but reaffirms the full-year EPS range of $19.50–$20.00. Shares drift within recent range.

Bear: MCR surprises above 89%, guidance is cut or the range is widened to the downside, and the call reveals that county-level exits have not adequately addressed cost concentration. Renewed pressure on the stock, with spillover into Humana and Elevance.

What Investors Should Watch

• Q3 medical care ratio versus the 86.7% posted in Q2 and the 89.9% recorded in Q3 2025
• Any update to 2027 Medicare Advantage membership guidance, especially recapture assumptions
• Management commentary on Optum Health cost trends, which drove margin deterioration in 2025
• Whether open enrollment signals, once October 15 arrives, show displaced members moving to remaining large carriers or toward traditional Medicare

Bottom Line

The exit wave settling across Medicare Advantage is not a crisis for UnitedHealth or Humana so much as a self-administered correction. Both companies are trading volume for margin. The October 13 report will show whether the Q2 medical cost improvement was durable or a favorable comparison distorted by prior-period reserve releases. That answer, more than any membership count, determines whether the pricing is working.